PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma

被引:59
作者
Abe, Azusa [1 ]
Minaguchi, Takeo [1 ]
Ochi, Hiroyuki [1 ]
Onuki, Mamiko [1 ]
Okada, Satoshi [1 ]
Matsumoto, Koji [1 ]
Satoh, Toyomi [1 ]
Oki, Akinori [1 ]
Yoshikawa, Hiroyuki [1 ]
机构
[1] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Obstet & Gynecol, Tsukuba, Ibaraki 3058575, Japan
关键词
PIK3CA; Ovarian clear cell carcinoma; Mutation; Amplification; Survival; PROMISING THERAPEUTIC TARGET; BREAST-CANCER; PTEN MUTATION; GENE; TRANSCRIPTION;
D O I
10.1016/j.humpath.2012.05.005
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Dysregulated signaling on the PI3-kinase/Akt cascade is reportedly associated with early stage and favorable prognosis in some kinds of malignancies including breast cancer, endometrial cancer, and colorectal cancer. PIK3CA, a catalytic subunit of PI3-kinase , is known to be activated in ovarian clear cell carcinoma (CCC), which is categorized as type I ovarian cancer. The aim of this study was to investigate the clinical significance of PIK3CA overexpression in the disease. We performed immunohistochemical analyses of PIK3CA, PTEN, p-Akt, p27 and p53 expressions in primary ovarian clear cell carcinomas from 62 Japanese patients. Genetic analyses of PIK3CA mutation and amplification were further conducted. PIK3CA was overexpressed in 45 tumors (73%), PTEN expression was negative in 3 (5%), and p53 was positive in 8 (13%). Overexpressed PIK3CA was found to be associated with p-Akt overexpression (P = .007). PIK3CA overexpression tended to be observed in more of stage I disease (73% versus 47%, P = .07) and was associated with absence of residual tumor at the initial surgery (96% versus 71%, P = .01 ). Furthermore, survival analyses revealed that PIK3CA overexpression correlated with improved overall survival (P = .03). Subsequent genetic analyses demonstrated that PIK3CA overexpression correlated with the presence of mutation or amplification of the PIK3CA gene in tumors (P = .009 ). Our observations suggest that the subgroup of ovarian clear cell carcinomas harboring activated PIK3CA seems to have better prognosis possibly due to more indolent biological property compared to tumors without PIK3CA activation. PIK3CA may serve as a biomarker for good prognosis and a possible therapeutic target in this lethal subtype of ovarian cancer. (c) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:199 / 207
页数:9
相关论文
共 19 条
[1]
Phosphorylated AKT Expression Is Associated With PIK3CA Mutation, Low Stage, and Favorable Outcome in 717 Colorectal Cancers [J].
Baba, Yoshifumi ;
Nosho, Katsuhiko ;
Shima, Kaori ;
Hayashi, Marika ;
Meyerhardt, Jeffrey A. ;
Chan, Andrew T. ;
Giovannucci, Edward ;
Fuchs, Charles S. ;
Ogino, Shuji .
CANCER, 2011, 117 (07) :1399-1408
[2]
Oncogenic PI3K deregulates transcription and translation [J].
Bader, AG ;
Kang, SY ;
Zhao, L ;
Vogt, PK .
NATURE REVIEWS CANCER, 2005, 5 (12) :921-929
[3]
Mutation of the PIK3CA gene in ovarian and breast cancer [J].
Campbell, IG ;
Russell, SE ;
Choong, DYH ;
Montgomery, KG ;
Ciavarella, ML ;
Hooi, CSF ;
Cristiano, BE ;
Pearson, RB ;
Phillips, WA .
CANCER RESEARCH, 2004, 64 (21) :7678-7681
[4]
Ovarian Cancer [J].
Cho, Kathleen R. ;
Shih, Ie-Ming .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2009, 4 :287-313
[5]
The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression [J].
Hui, Rosaline C. -Y. ;
Gomes, Ana R. ;
Constantinidou, Demetra ;
Costa, Joana R. ;
Karadedou, Christina T. ;
de Mattos, Silvia Fernandez ;
Wymann, Matthias P. ;
Brosens, Jan J. ;
Schulze, Almut ;
Lam, Eric W. -F. .
MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (19) :5886-5898
[6]
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer [J].
Kalinsky, Kevin ;
Jacks, Lindsay M. ;
Heguy, Adriana ;
Patil, Sujata ;
Drobnjak, Marija ;
Bhanot, Umeshkumar K. ;
Hedvat, Cyrus V. ;
Traina, Tiffany A. ;
Solit, David ;
Gerald, William ;
Moynahan, Mary Ellen .
CLINICAL CANCER RESEARCH, 2009, 15 (16) :5049-5059
[7]
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma [J].
Kuo, Kuan-Ting ;
Mao, Tsui-Lien ;
Jones, Sian ;
Veras, Emanuela ;
Ayhan, Ayse ;
Wang, Tian-Li ;
Glas, Ruth ;
Slamon, Dennis ;
Velculescu, Victor E. ;
Kuman, Robert J. ;
Shih, Ie-Ming .
AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (05) :1597-1601
[8]
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer [J].
Loi, Sherene ;
Haibe-Kains, Benjamin ;
Majjaj, Samira ;
Lallemand, Francoise ;
Durbecq, Virginie ;
Larsimont, Denis ;
Gonzalez-Angulo, Ana M. ;
Pusztai, Lajos ;
Symmans, W. Fraser ;
Bardelli, Alberto ;
Ellis, Paul ;
Tutt, Andrew N. J. ;
Gillett, Cheryl E. ;
Hennessy, Bryan T. ;
Mills, Gordon B. ;
Phillips, Wayne A. ;
Piccart, Martine J. ;
Speed, Terence P. ;
McArthur, Grant A. ;
Sotiriou, Christos .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (22) :10208-10213
[9]
Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary [J].
Mabuchi, Seiji ;
Kawase, Chiaki ;
Altomare, Deborah A. ;
Morishige, Kenichirou ;
Hayashi, Masami ;
Sawada, Kenjiro ;
Ito, Kimihiko ;
Terai, Yoshito ;
Nishio, Yukihiro ;
Klein-Szanto, Andres J. ;
Burger, Robert A. ;
Ohmichi, Masahide ;
Testa, Joseph R. ;
Kimura, Tadashi .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (08) :2411-2422
[10]
mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary [J].
Mabuchi, Seiji ;
Kawase, Chiaki ;
Altomare, Deborah A. ;
Morishige, Kenichirou ;
Sawada, Kenjiro ;
Hayashi, Masami ;
Tsujimoto, Masahiko ;
Yamoto, Mareo ;
Klein-Szanto, Andres J. ;
Schilder, Russell J. ;
Ohmichi, Masahide ;
Testa, Joseph R. ;
Kimura, Tadashi .
CLINICAL CANCER RESEARCH, 2009, 15 (17) :5404-5413